{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:50:39Z","timestamp":1787986239255,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T00:00:00Z","timestamp":1653177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T00:00:00Z","timestamp":1653177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS124882"],"award-info":[{"award-number":["R01NS124882"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS098023"],"award-info":[{"award-number":["R01NS098023"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40120-022-00358-4","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T08:02:33Z","timestamp":1653206553000},"page":"1147-1165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010\u20132019"],"prefix":"10.1007","volume":"11","author":[{"given":"Wen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rock A.","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangho","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1500-2589","authenticated-orcid":false,"given":"Zongqi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,22]]},"reference":[{"key":"358_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.18553\/jmcp.2010.16.9.703","volume":"16","author":"CV Asche","year":"2010","unstructured":"Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16:703\u201312. https:\/\/doi.org\/10.18553\/jmcp.2010.16.9.703.","journal-title":"J Manag Care Pharm"},{"key":"358_CR2","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","volume":"84","author":"DM Hartung","year":"2015","unstructured":"Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology. 2015;84:2185\u201392. https:\/\/doi.org\/10.1212\/WNL.0000000000001608.","journal-title":"Neurology"},{"key":"358_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169\u201380. https:\/\/doi.org\/10.1056\/NEJMra1401483.","journal-title":"N Engl J Med"},{"key":"358_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90:777\u201388. https:\/\/doi.org\/10.1212\/WNL.0000000000005347.","journal-title":"Neurology"},{"key":"358_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(08)61620-7.","journal-title":"Lancet"},{"key":"358_CR6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1212\/01.wnl.0000218309.01322.5c","volume":"66","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696\u2013702. https:\/\/doi.org\/10.1212\/01.wnl.0000218309.01322.5c.","journal-title":"Neurology"},{"key":"358_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159129","volume":"11","author":"O Ernstsson","year":"2016","unstructured":"Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis\u2014a systematic review. PLoS\u00a0One. 2016;11: e0159129. https:\/\/doi.org\/10.1371\/journal.pone.0159129.","journal-title":"PLoS\u00a0One"},{"key":"358_CR8","first-page":"644","volume":"90","author":"A Saguil","year":"2014","unstructured":"Saguil A, Kane S, Farnell E. Multiple sclerosis: a primary care perspective. Am Fam Physician. 2014;90:644\u201352.","journal-title":"Am Fam Physician"},{"key":"358_CR9","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s13311-017-0566-3","volume":"14","author":"DM Hartung","year":"2017","unstructured":"Hartung DM. Economics and cost-effectiveness of multiple sclerosis therapies in the USA. Neurotherapeutics. 2017;14:1018\u201326. https:\/\/doi.org\/10.1007\/s13311-017-0566-3.","journal-title":"Neurotherapeutics"},{"key":"358_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/1472-6963-14-286","volume":"14","author":"CA Carroll","year":"2014","unstructured":"Carroll CA, Fairman KA, Lage MJ. Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data. BMC Health Serv Res. 2014;14:286. https:\/\/doi.org\/10.1186\/1472-6963-14-286.","journal-title":"BMC Health Serv Res"},{"key":"358_CR11","first-page":"s307","volume":"19","author":"GM Owens","year":"2013","unstructured":"Owens GM. Managed care aspects of managing multiple sclerosis. Am J Manag Care. 2013;19:s307-312.","journal-title":"Am J Manag Care"},{"key":"358_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/CEOR.S55779","volume":"6","author":"MM Bonafede","year":"2013","unstructured":"Bonafede MM, Johnson BH, Watson C. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. Clinicoecon Outcomes Res. 2013;6:11\u201320. https:\/\/doi.org\/10.2147\/CEOR.S55779.","journal-title":"Clinicoecon Outcomes Res"},{"key":"358_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1212\/WNL.0b013e3182270402","volume":"77","author":"K Noyes","year":"2011","unstructured":"Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology. 2011;77:355\u201363. https:\/\/doi.org\/10.1212\/WNL.0b013e3182270402.","journal-title":"Neurology"},{"key":"358_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(17)30076-5","volume":"16","author":"JMA Wijnands","year":"2017","unstructured":"Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 2017;16:445\u201351. https:\/\/doi.org\/10.1016\/S1474-4422(17)30076-5.","journal-title":"Lancet Neurol"},{"key":"358_CR15","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2165\/11538000-000000000-00000","volume":"70","author":"J Sharac","year":"2010","unstructured":"Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010;70:1677\u201391. https:\/\/doi.org\/10.2165\/11538000-000000000-00000.","journal-title":"Drugs"},{"key":"358_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211063403","author":"HS Ng","year":"2021","unstructured":"Ng HS, Zhu F, Kingwell E, et al. Disease-modifying drugs for multiple sclerosis and subsequent health service use. Mult Scler. 2021. https:\/\/doi.org\/10.1177\/13524585211063403.","journal-title":"Mult Scler"},{"key":"358_CR17","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123\u201336. https:\/\/doi.org\/10.1177\/1352458517694432.","journal-title":"Mult Scler"},{"key":"358_CR18","unstructured":"The Institute for Clinical and Economic Review. Disease-modifying therapies for relapsing remitting and primary-progressive multiple sclerosis: effectiveness and value. 2017. https:\/\/icer.org\/assessment\/multiple-sclerosis-2017. Accessed 14 Mar 2022."},{"key":"358_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/9781119959946.ch13","volume-title":"Pharmacoepidemiology","author":"J Seeger","year":"2012","unstructured":"Seeger J, Daniels G. Commercial databases. In: Strom B, Hennessey S, Kimmel S, editors. Pharmacoepidemiology. 5th ed. Chichester: Wiley; 2012. p. 189\u2013208.","edition":"5"},{"key":"358_CR20","doi-asserted-by":"publisher","first-page":"e1016","DOI":"10.1212\/WNL.0000000000007043","volume":"92","author":"WJ Culpepper","year":"2019","unstructured":"Culpepper WJ, Marrie RA, Langer-Gould A, et al. Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 2019;92:e1016\u201328. https:\/\/doi.org\/10.1212\/WNL.0000000000007043.","journal-title":"Neurology"},{"key":"358_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536\u201341. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4905.","journal-title":"JAMA Neurol"},{"key":"358_CR22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3111\/13696998.2010.523670","volume":"13","author":"BJ Chastek","year":"2010","unstructured":"Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13:618\u201325. https:\/\/doi.org\/10.3111\/13696998.2010.523670.","journal-title":"J Med Econ"},{"key":"358_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2147\/CEOR.S163907","volume":"10","author":"C Chen","year":"2018","unstructured":"Chen C, Wu N, Watson C. Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon. Clinicoecon Outcomes Res. 2018;10:723\u201330. https:\/\/doi.org\/10.2147\/CEOR.S163907.","journal-title":"Clinicoecon Outcomes Res"},{"key":"358_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00251-w","author":"L Freeman","year":"2021","unstructured":"Freeman L, Kee A, Tian M, Mehta R. Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy. Drugs Real World Outcomes. 2021. https:\/\/doi.org\/10.1007\/s40801-021-00251-w.","journal-title":"Drugs Real World Outcomes"},{"key":"358_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/big.2013.0024","volume":"1","author":"R Higdon","year":"2013","unstructured":"Higdon R, Stewart E, Roach J, et al. Predictive analytics in healthcare: medications as a predictor of medical complexity. Big Data. 2013;1:237\u201344.","journal-title":"Big Data"},{"key":"358_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/1475-6773.12612","volume":"53","author":"A Dunn","year":"2018","unstructured":"Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res. 2018;53:175\u201396. https:\/\/doi.org\/10.1111\/1475-6773.12612.","journal-title":"Health Serv Res"},{"key":"358_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1377\/hlthaff.2018.05499","volume":"38","author":"AM Sisko","year":"2019","unstructured":"Sisko AM, Keehan SP, Poisal JA, et al. National health expenditure projections, 2018\u201327: economic and demographic trends drive spending and enrollment growth. Health Aff (Millwood). 2019;38:491\u2013501. https:\/\/doi.org\/10.1377\/hlthaff.2018.05499.","journal-title":"Health Aff (Millwood)"},{"key":"358_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1352458511419702","volume":"18","author":"J Correale","year":"2012","unstructured":"Correale J, Peirano I, Romano L. Benign multiple sclerosis: a new definition of this entity is needed. Mult Scler. 2012;18:210\u20138. https:\/\/doi.org\/10.1177\/1352458511419702.","journal-title":"Mult Scler"},{"key":"358_CR29","doi-asserted-by":"publisher","first-page":"175628642098703","DOI":"10.1177\/1756286420987031","volume":"14","author":"DM Hartung","year":"2021","unstructured":"Hartung DM. Health economics of disease-modifying therapy for multiple sclerosis in the United States. Ther Adv Neurol Disord. 2021;14:1756286420987031. https:\/\/doi.org\/10.1177\/1756286420987031.","journal-title":"Ther Adv Neurol Disord"},{"key":"358_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.msard.2019.02.006","volume":"30","author":"Y Kim","year":"2019","unstructured":"Kim Y, Krause TM, Blum P, Freeman L. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis. Mult Scler Relat Disord. 2019;30:69\u201375. https:\/\/doi.org\/10.1016\/j.msard.2019.02.006.","journal-title":"Mult Scler Relat Disord"},{"key":"358_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2711","author":"A San-Juan-Rodriguez","year":"2019","unstructured":"San-Juan-Rodriguez A, Good CB, Heyman RA, et al. Trends in prices, market share, and spending on self-administered disease-modifying therapies for multiple sclerosis in medicare part D. JAMA Neurol. 2019. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2711.","journal-title":"JAMA Neurol"},{"key":"358_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.34627","volume":"4","author":"J Hou","year":"2021","unstructured":"Hou J, Kim N, Cai T, et al. Comparison of dimethyl fumarate vs fingolimod and rituximab vs natalizumab for treatment of multiple sclerosis. JAMA Netw Open. 2021;4: e2134627. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.34627.","journal-title":"JAMA Netw Open"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00358-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00358-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00358-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:00:10Z","timestamp":1659106810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00358-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,22]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00358-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,22]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}